Most cited papers from Debiopharm (Switzerland)

Debiopharm (Switzerland)

What are the most cited papers from Debiopharm (Switzerland)?

The most cited paper from Debiopharm (Switzerland) is "Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data" (Julie-Anne Quinn, Flor M. Muñoz, Bernard Gonik et al., 2016), with 508 citations. Next come "Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines" (435) and "Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy" (359).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 54 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data Julie-Anne Quinn, Flor M. Muñoz, Bernard Gonik et al. · Vaccine Open access	16 Oct 2016	508
2	Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines D. Machover, Eduardo Díaz‐Rubio, Aimery de Gramont et al. · Annals of Oncology Open access	1996	435
3	Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy Douglas P. Millay, Michelle A. Sargent, Hanna E. Osińska et al. · Nature Medicine Open access	16 Mar 2008	359
4	Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives Elidie Béard, Sylvain Lengacher, Sara Dias et al. · Frontiers in Physiology Open access	10 Jan 2022	317
5	Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat Guido Cavaletti, G Tredici, M G Petruccioli et al. · European Journal of Cancer	Dec 2001	289
6	The non‐immunosuppressive cyclosporin DEBIO‐025 is a potent inhibitor of hepatitis C virus replication in vitro† Jan Paeshuyse, Artur Kaul, Erik De Clercq et al. · Hepatology Open access	23 Mar 2006	279
7	Cyclosporine A delivery to the eye: A pharmaceutical challenge Frédéric Lallemand, Olivia Felt-Baeyens, Kamel Besseghir et al. · European Journal of Pharmaceutics and Biopharmaceutics	16 Sep 2003	239
8	Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP Rajarshi Mukherjee et al. · Gut Open access	12 Jun 2015	232
9	Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study Eduardo Díaz‐Rubio, Javier Sastre, Alberto Zaniboni et al. · Annals of Oncology Open access	1998	228
10	The cyclophilin inhibitor Debio-025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Robert Flisiak, Andrzej Horban, Philippe A. Gallay et al. · Hepatology	7 Feb 2008	225
11	The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients # Robert Flisiak, Saya V. Feinman, Maciej Jabłkowski et al. · Hepatology Open access	4 Feb 2009	225
12	Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate Francis Lévi, Bruno Perpoint, Carlo Garufi et al. · European Journal of Cancer	1993	220
13	Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer Kyle Clifford Cuneo, Meredith Ann Morgan, Vaibhav Sahai et al. · Journal of Clinical Oncology Open access	9 Aug 2019	203
14	The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication Udayan Chatterji, Michael D. Bobardt, Suganya Selvarajah et al. · Journal of Biological Chemistry Open access	21 Apr 2009	202
15	DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A Lotte Coelmont, Xavier Hanoulle, Udayan Chatterji et al. · PLoS ONE Open access	27 Oct 2010	186
16	Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer Philippe J. M. Chollet, M.A. Bensmaïne, Silvano Brienza et al. · Annals of Oncology Open access	Dec 1996	140
17	The Nonimmunosuppressive Cyclosporin Analogs NIM811 and UNIL025 Display Nanomolar Potencies on Permeability Transition in Brain-Derived Mitochondria Magnus Joakim Hansson, Gustav Mattiasson, Roland Månsson et al. · Journal of Bioenergetics and Biomembranes	Aug 2004	140
18	A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma Francis L�vi, Rachid Zidani, Silvano Brienza et al. · Cancer Open access	15 Jun 1999	134
19	Truncated FGFR2 is a clinically actionable oncogene in multiple cancers Daniel Zingg et al. · Nature Open access	10 Aug 2022	133
20	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours Mark T. J. van Bussel, Ahmad Hussein Awada, Maja J.A. de Jonge et al. · British Journal of Cancer Open access	23 Nov 2020	130
21	Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study Xu-Shan Sun et al. · The Lancet Oncology	3 Aug 2020	130
22	Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters Dorothea Werdenberg, Rajesh Kumar Joshi, Siegfried Wolffram et al. · Biopharmaceutics & Drug Disposition	6 Jun 2003	128
23	Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors Lotte Coelmont, Suzanne J. F. Kaptein, Jan Paeshuyse et al. · Antimicrobial Agents and Chemotherapy Open access	23 Dec 2008	127
24	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations Martin Henner Voss, Cinta Hierro, Rebecca Suk Heist et al. · Clinical Cancer Research Open access	11 Feb 2019	122
25	The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects inCol6a1−/−myopathic mice Tania Tiepolo, Alessia Angelin, Elena Palma et al. · British Journal of Pharmacology Open access	10 Jun 2009	122
26	HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors Udayan Chatterji, Precious J. Lim, Michael D. Bobardt et al. · Journal of Hepatology Open access	4 Apr 2010	121
27	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent Roger G. Ptak, Philippe A. Gallay, Dirk Jochmans et al. · Antimicrobial Agents and Chemotherapy Open access	23 Jan 2008	115
28	FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma James M. Cleary et al. · Cancer Discovery Open access	29 Apr 2021	110
29	Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer Chris F. Heyns, Marie-Paule Simonin, Pierre Grosgurin et al. · British Journal of Urology	23 Jul 2003	105
30	Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants Alexandra Rothen-Weinhold, Kamel Besseghir, Evelyne Vuaridel et al. · European Journal of Pharmaceutics and Biopharmaceutics Open access	Sep 1999	103
31	Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy J. Reutenauer, Olivier M. Dorchies, Ophélie Patthey-Vuadens et al. · British Journal of Pharmacology Open access	21 Jul 2008	101
32	ENaC‐mediated alveolar fluid clearance and lung fluid balance depend on the channel‐activating protease 1 Carole Planès, Nadia Randrianarison, Roch‐Philippe Charles et al. · EMBO Molecular Medicine Open access	9 Nov 2009	100
33	PEG–Ara-C conjugates for controlled release Oddone Schiavon, Gianfranco Pasut, Stefano Moro et al. · European Journal of Medicinal Chemistry	15 Jan 2004	99
34	Evaluation of a cyclophilin inhibitor in hepatitis C virus–infected chimeric mice in vivo† Kazuaki Inoue, Takuya Umehara, Urs T. Rüegg et al. · Hepatology Open access	28 Mar 2007	95
35	A Novel Neutrophil Elastase Inhibitor Prevents Elastase Activation and Surface Cleavage of the Epithelial Sodium Channel Expressed in Xenopus laevis Oocytes M. Scott Harris, Dmitri Firsov, Grégoire Vuagniaux et al. · Journal of Biological Chemistry Open access	8 Nov 2006	94
36	Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres María J. Blanco‐Prieto, Miguel Ángel Campanero, Kamel Besseghir et al. · Journal of Controlled Release Open access	30 Mar 2004	93
37	Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers I Trinchard-Lugan, Abad Khan, H C Porchet et al. · Reproductive BioMedicine Online Open access	2002	84
38	Molecular Determinants of the Cytotoxicity of Platinum Compounds Antoine Vekris, Delphine Meynard, Marie‐Christine Haaz et al. · Cancer Research	2004	82
39	Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model Giovanna Sociali, Mirko Magnone, Silvia Ravera et al. · The FASEB Journal Open access	6 Apr 2017	81
40	Understanding Long COVID; Mitochondrial Health and Adaptation—Old Pathways, New Problems Alistair V.W. Nunn, Geoffrey W. Guy, Wolfgang Brysch et al. · Biomedicines Open access	2 Dec 2022	77
41	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study Herbert I. Hurwitz, David C. Smith, Henry Clement Pitot et al. · Cancer Chemotherapy and Pharmacology Open access	26 Feb 2015	77
42	First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma Michael S. Hofman, Ben Tran, Darren Richard Feldman et al. · Journal of Nuclear Medicine Open access	22 Feb 2024	74
43	Combination of lentivector immunization and low‐dose chemotherapy or PD‐1/PD‐L1 blocking primes self‐reactive T cells and induces anti‐tumor immunity Sophie R. Sierro, Alena Donda, Rachel Perret et al. · European Journal of Immunology Open access	2 May 2011	72
44	Naturally Occurring Capsid Substitutions Render HIV-1 Cyclophilin A Independent in Human Cells and TRIM-cyclophilin-resistant in Owl Monkey Cells Udayan Chatterji, Michael D. Bobardt, Robyn L. Stanfield et al. · Journal of Biological Chemistry Open access	Oct 2005	71
45	The PIDDosome, DNA-damage-induced apoptosis and beyond Sophie Janssens, Antoine Tinel · Cell Death and Differentiation Open access	18 Nov 2011	71
46	DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death Benoît Thibault, Ludivine Genre, Augustin Le Naour et al. · Scientific Reports Open access	10 Dec 2018	69
47	Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? Alexander Schuhmacher, Oliver Gassmann, Nigel William McCracken et al. · Journal of Translational Medicine Open access	8 May 2018	68
48	Nanocrystals of a potent p38 MAPK inhibitor embedded in microparticles: Therapeutic effects in inflammatory and mechanistic murine models of osteoarthritis Pierre Maudens, Christian Alexander Seemayer, François Pfefferlé et al. · Journal of Controlled Release Open access	7 Mar 2018	68
49	Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis Marion David, Johnny Ribeiro, Françoise Descôtes et al. · International Journal of Oncology Open access	20 Dec 2011	67
50	Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice Erin R. Wissing, Douglas P. Millay, Grégoire Vuagniaux et al. · Neuromuscular Disorders Open access	16 Jul 2010	66

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.